Polsinelli Represents Merck in Launch of Merck Wilmington Biotech

Polsinelli recently represented Merck & Co., Inc., Rahway, N.J. (Merck), a global health care company that uses cutting-edge science to develop vaccines, pharmaceuticals, biologic therapies and animal health products, in the successful closing of Merck Wilmington Biotech, a $1 billion state-of-the-art, center-of-excellence biologics facility.

Located at Chestnut Run Innovation & Science Park, in Wilmington, Del., the 470,000 square-foot facility comprises laboratory, manufacturing and warehousing capabilities, and is anticipated to enable Merck to manufacture KEYTRUDA in the United States, as well as to launch and expand the production of next-generation biologics and therapies.

More information about this transaction can be found here.

Shareholder Marcy Hart led the Polsinelli deal team in this matter, which also included Shareholder Brooks S. Clark.